MRSNY;MAHMOOD, TAHIR; RANDALL J.;MRSNY, RANDALL J.
发明人:
MRSNY, RANDALL J.,MAHMOOD, TAHIR
申请号：
EP11825567
公开号：
EP2616045A4
申请日:
2011.09.15
申请国别(地区):
EP
年份:
2014
代理人:
摘要：
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections； the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required； and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.
